Latest & greatest articles for travoprost

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on travoprost or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on travoprost and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for travoprost

1. Efficacy of travoprost for patients with glaucoma: an updated systematic review protocol of randomized controlled trials

Efficacy of travoprost for patients with glaucoma: an updated systematic review protocol of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

2. Travoprost

Travoprost Top results for travoprost - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for travoprost The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

3. travoprost ophthalmic solution (Izba)

travoprost ophthalmic solution (Izba) travoprost ophthalmic solution | CADTH.ca Find the information you need travoprost ophthalmic solution travoprost ophthalmic solution Last Updated: January 31, 2017 Result type: Reports Project Number: SR0516-000 Product Line: Generic Name: travoprost ophthalmic solution Brand Name: Izba Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: open-angle glaucoma Submission Type: New Project Status: Complete Date Recommendation Issued: October 25 (...) , 2017 Recommendation Type: Reimburse with clinical criteria and/or conditions Tags eye, glaucoma, ocular hypertension, prostaglandins, Izba, Open-Angle, Synthetic, travoprost Files Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

4. TRAVATAN (travoprost), glaucoma eye drops

TRAVATAN (travoprost), glaucoma eye drops Haute Autorité de Santé - TRAVATAN (travoprost), collyre anti-glaucomateux Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments TRAVATAN (travoprost), collyre anti-glaucomateux Substance active (DCI) travoprost OPHTALMOLOGIE - Nouvelle indication Nature de la demande Extension d'indication Avis de la CT (...) à la démonstration de non infériorité du travoprost par rapport au timolol après 12 semaines de traitement sur la réduction de la pression intraoculaire chez l’enfant, la Commission considère que TRAVATAN (travoprost) n’apporte pas d’amélioration du service médical rendu (ASMR V) dans la stratégie thérapeutique de prise en charge des patients pédiatriques ayant une pression intraoculaire élevée et souffrant de glaucome pédiatrique qui comprend la chirurgie et les collyres anti glaucomateux

2016 Haute Autorite de sante

5. Travoprost (Travatan) - for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma

Travoprost (Travatan) - for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma Final Appraisal Recommendation Advice No: 3115 – October 2015 Travoprost (Travatan ® ) 40 micrograms/ml eye drops, solution Limited submission by Alcon Laboratories (UK) Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation (...) and will be considered for review every three years. Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3115: Travoprost (Travatan ® ) 40 micrograms/ml eye drops, solution. October 2015. Recommendation of AWMSG Travoprost (Travatan ® ) is recommended as an option for use within NHS Wales for the decrease of elevated intraocular pressure in paediatric patients aged 2

2015 All Wales Medicines Strategy Group

6. Travoprost (Travatan®)

Travoprost (Travatan®) Travoprost (Travatan®) Travoprost (Travatan®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Travoprost (Travatan®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 2601. 2015 Authors' conclusions Travoprost (Travatan®) is recommended as an option for use within NHS Wales for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cloprostenol; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Prostaglandins F, Synthetic; Wales Language Published

2015 Health Technology Assessment (HTA) Database.

7. Izba - travoprost

Izba - travoprost 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu 19 December 2013 EMA/13480/2014 Committee for Medicinal Products for Human Use (CHMP) Assessment report Izba International non-proprietary name: travoprost Procedure No. EMEA/H/C/002738/0000 Note Assessment report as adopted by the CHMP with all information (...) of a commercially confidential nature deleted Izba Assessment Report EMA/13480/2014 Page 2/62 Product information Name of the medicinal product: Izba Applicant: Alcon Laboratories (UK) Ltd Frimley Business Park Frimley Camberley GU16 7SR UNITED KINGDOM Active substance: travoprost International Nonproprietary Name: travoprost Pharmaco-therapeutic group (ATC Code): Travoprost (S01EE04) Therapeutic indication(s): Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle

2014 European Medicines Agency - EPARs

8. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database

Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment (...) persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Lafuma A, Salmon JF, Robert J, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

Full Text available with Trip Pro

2011 NHS Economic Evaluation Database.

9. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database

Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients (...) with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database De Natale R, Lafuma A, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of travoprost

2009 NHS Economic Evaluation Database.

10. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France

Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Payet S, Denis P, Berdeaux G, Launois R Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the costs and effects of travoprost and latanoprost as single treatments for glaucoma in France. The authors concluded that travoprost was very cost-effective, producing fewer treatment changes, at a small increase in cost, which was acceptable

2008 NHS Economic Evaluation Database.

11. Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database

Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination (...) and effectiveness of travoprost versus dorzolamide and timolol. The authors concluded that travoprost dominated dorzolamide and timolol, as it was both more effective and less costly. Although the authors used a retrospective design, the methodology was good and appropriate statistical methods were used to control for biases. The methods and results were well reported and the conclusions appear to be appropriate. Type of economic evaluation Cost-effectiveness analysis Study objective The objective

2007 NHS Economic Evaluation Database.

12. Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom

Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Cost-effectiveness and cost-utility analysis (...) of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Le Pen C, Ligier M, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn

2005 NHS Economic Evaluation Database.

13. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects

Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Halpern M T, Covert D W, Robin A L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of travoprost 0.004% (Travatan) as an intraocular pressure (IOP)-lowering treatment for visual field deficit (VFD) progression among people with glaucoma. Individuals received one drop of travoprost in each eye

2002 NHS Economic Evaluation Database.

14. Travatan (Travoprost) Ophthalmic Solution

Travatan (Travoprost) Ophthalmic Solution Drug Approval Package: Travatan (Travoprost) NDA #21-257 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Travatan (Travoprost) Ophthalmic Solution Company: Alcon Application No.: 21-257 Approval Date: 3/16/2001 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 20, 2001 Note: Documents in PDF format require the . - - Links

2001 FDA - Drug Approval Package